NuCana Gestione
Gestione criteri di controllo 3/4
NuCana's CEO is Hugh Griffith, appointed in Mar 2008, has a tenure of 16.67 years. total yearly compensation is £974.59K, comprised of 58.9% salary and 41.1% bonuses, including company stock and options. directly owns 2.25% of the company’s shares, worth $77.93K. The average tenure of the management team and the board of directors is 4.1 years and 6.5 years respectively.
Informazioni chiave
Hugh Griffith
Amministratore delegato
UK£974.6k
Compenso totale
| Percentuale dello stipendio del CEO | 58.9% |
| Mandato del CEO | 16.7yrs |
| Proprietà del CEO | 2.3% |
| Durata media del management | 4.1yrs |
| Durata media del Consiglio di amministrazione | 6.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?
Aug 21
Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely
Mar 14We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate
Oct 15Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation
Jul 01Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
Mar 15Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
Nov 30NuCana: An Intriguing 'Sum Of The Parts' Story
Sep 22NuCana GAAP EPS of -£0.07
Aug 17NuCana regains Nasdaq compliance
Jul 27NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead
Jul 13Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
May 02We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth
Jan 17NuCana: Preparing For A Critical 2022
Dec 08We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow
Sep 30NuCana: The Market Continues To Overlook Its ProTide Platform Technology
Sep 11We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth
Jun 01Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth
Feb 15How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?
Dec 22
NuCana (NCNA) Investor Presentation - Slideshow
Dec 02NuCana reports Q3 results
Nov 19Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£28m |
| Mar 31 2024 | n/a | n/a | -UK£27m |
| Dec 31 2023 | UK£975k | UK£574k | -UK£28m |
| Sep 30 2023 | n/a | n/a | -UK£35m |
| Jun 30 2023 | n/a | n/a | -UK£33m |
| Mar 31 2023 | n/a | n/a | -UK£31m |
| Dec 31 2022 | UK£1m | UK£552k | -UK£32m |
| Sep 30 2022 | n/a | n/a | -UK£30m |
| Jun 30 2022 | n/a | n/a | -UK£34m |
| Mar 31 2022 | n/a | n/a | -UK£39m |
| Dec 31 2021 | UK£907k | UK£531k | -UK£41m |
| Sep 30 2021 | n/a | n/a | -UK£39m |
| Jun 30 2021 | n/a | n/a | -UK£40m |
| Mar 31 2021 | n/a | n/a | -UK£36m |
| Dec 31 2020 | UK£920k | UK£551k | -UK£31m |
| Sep 30 2020 | n/a | n/a | -UK£26m |
| Jun 30 2020 | n/a | n/a | -UK£22m |
| Mar 31 2020 | n/a | n/a | -UK£20m |
| Dec 31 2019 | UK£828k | UK£498k | -UK£21m |
| Sep 30 2019 | n/a | n/a | -UK£17m |
| Jun 30 2019 | n/a | n/a | -UK£16m |
| Mar 31 2019 | n/a | n/a | -UK£13m |
| Dec 31 2018 | UK£786k | UK£467k | -UK£14m |
| Sep 30 2018 | n/a | n/a | -UK£15m |
| Jun 30 2018 | n/a | n/a | -UK£26m |
| Mar 31 2018 | n/a | n/a | -UK£28m |
| Dec 31 2017 | UK£635k | UK£330k | -UK£23m |
Compensazione vs Mercato: Hugh's total compensation ($USD1.26M) is above average for companies of similar size in the US market ($USD655.65K).
Compensazione vs guadagni: Hugh's compensation has been consistent with company performance over the past year.
AMMINISTRATORE DELEGATO
Hugh Griffith (56 yo)
16.7yrs
Mandato
UK£974,586
Compensazione
Mr. Hugh Stephen Griffith is Founder of NuCana plc (formerly, NuCana BioMed Limited) and has been its Chief Executive Officer since March 2008. Mr. Griffith was also the Chief Executive Officer at Alida Ca...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 16.7yrs | UK£974.59k | 2.25% $ 77.9k | |
| Chief Financial Officer | 9.1yrs | Nessun dato | 0.28% $ 9.5k | |
| Head of Translational Medicine | 6.9yrs | Nessun dato | 0% $ 0 | |
| Chief Medical Officer | 3.3yrs | Nessun dato | 0.00018% $ 6.2 | |
| Senior Vice President of Clinical Operations | 4.8yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Medical & Clinical Development | 4.1yrs | Nessun dato | Nessun dato | |
| Senior VP of Strategy & Lifecycle Management | less than a year | Nessun dato | Nessun dato | |
| Senior VP of CMC & Development | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Regulatory Affairs | less than a year | Nessun dato | Nessun dato | |
| Company Secretary | no data | Nessun dato | Nessun dato |
4.1yrs
Durata media
60yo
Età media
Gestione esperta: NCNA's management team is considered experienced (4.1 years average tenure).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 16.7yrs | UK£974.59k | 2.25% $ 77.9k | |
| Independent Non-Executive Chairman | 3.9yrs | UK£78.77k | 0% $ 0 | |
| Independent Non-Executive Director | 14.9yrs | UK£47.85k | 0.050% $ 1.7k | |
| Independent Non Executive Director | 6.6yrs | UK£56.56k | 0% $ 0 | |
| Independent Non-Executive Director | 4.2yrs | UK£29.25k | 0.00098% $ 33.9 | |
| Independent Director | 3yrs | UK£54.23k | 0.0084% $ 289.6 | |
| Independent Non Executive Director | 6.5yrs | UK£65.08k | 0% $ 0 |
6.5yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: NCNA's board of directors are considered experienced (6.5 years average tenure).